The Association of the British Pharmaceutical Industry (ABPI) ads

Alzheimer’s devastates the lives of patients and their families, costing billions in care. New treatments that can slow the disease’s progression in its early stages have recently been licensed in the UK - yet NHS patients are still being denied access, even though these therapies are available in other countries. Reviewing how these medicines are valued is a first step towards bringing UK patients treatments that could give them the chance of better lives.

Acid Sphingomyelinase Deficiency (ASMD) is a rare disease that limits and shortens the lives of children and adults. Breakthrough treatments can halt symptoms and reverse disease progression. Despite clear clinical benefits, many UK patients still cannot access these medicines, even though they are available in over 50 countries including France, Germany and Australia. Changing the way treatments like these are valued is the first step in giving UK patients with rare diseases a chance of an improved quality of life.

Alzheimer’s devastates the lives of patients and their families, costing billions in care. New treatments that can slow the disease’s progression in its early stages have recently been licensed in the UK - yet NHS patients are still being denied access, even though these therapies are available in other countries. Reviewing how these medicines are valued is a first step towards bringing UK patients treatments that could give them the chance of better lives.

New breast cancer treatments can extend patients’ lives, yet some remain unavailable in parts of the UK, even though people in the US and many European countries can access them. Rethinking the way such medicines are valued and approved is a crucial first step in increasing access to life-extending care for more UK patients.

Acid Sphingomyelinase Deficiency (ASMD) is a rare disease that limits and shortens the lives of children and adults. Breakthrough treatments can halt symptoms and reverse disease progression. Despite clear clinical benefits, many UK patients still cannot access these medicines, even though they are available in over 50 countries including France, Germany and Australia. Changing the way treatments like these are valued is the first step in giving UK patients with rare diseases a chance of an improved quality of life.

New breast cancer treatments can extend patients’ lives, yet some remain unavailable in parts of the UK, even though people in the US and many European countries can access them. Rethinking the way such medicines are valued and approved is a crucial first step in increasing access to life-extending care for more UK patients.